CONMED (NASDAQ:CNMD – Get Rating) is one of 71 publicly-traded companies in the “Electromedical equipment” industry, but how does it contrast to its competitors? We will compare CONMED to similar companies based on the strength of its earnings, profitability, institutional ownership, analyst recommendations, dividends, valuation and risk.
Dividends
CONMED pays an annual dividend of $0.80 per share and has a dividend yield of 0.8%. CONMED pays out -28.2% of its earnings in the form of a dividend. As a group, “Electromedical equipment” companies pay a dividend yield of 2.3% and pay out -326.3% of their earnings in the form of a dividend. CONMED lags its competitors as a dividend stock, given its lower dividend yield and higher payout ratio.
Profitability
This table compares CONMED and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CONMED | -7.71% | 11.39% | 3.94% |
| CONMED Competitors | -659.83% | -48.46% | -23.66% |
Earnings and Valuation
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| CONMED | $1.05 billion | -$80.58 million | -33.86 |
| CONMED Competitors | $1.05 billion | $117.16 million | 5.33 |
CONMED’s competitors have higher revenue and earnings than CONMED. CONMED is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Volatility & Risk
CONMED has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500. Comparatively, CONMED’s competitors have a beta of 13.27, suggesting that their average share price is 1,227% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings for CONMED and its competitors, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CONMED | 0 | 0 | 0 | 0 | N/A |
| CONMED Competitors | 109 | 636 | 1772 | 79 | 2.70 |
As a group, “Electromedical equipment” companies have a potential upside of 66.16%. Given CONMED’s competitors higher possible upside, analysts clearly believe CONMED has less favorable growth aspects than its competitors.
Insider & Institutional Ownership
47.6% of shares of all “Electromedical equipment” companies are owned by institutional investors. 4.9% of CONMED shares are owned by insiders. Comparatively, 12.4% of shares of all “Electromedical equipment” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
CONMED competitors beat CONMED on 9 of the 12 factors compared.
About CONMED
CONMED Corp. operates as a medical technology company, which engages in the development, manufacturing, and sale of surgical devices and related equipment. It operates through the United States, Europe, Middle East, and Africa, and Asia Pacific geographical segments. Its products are used by surgeons and physicians in a variety of medical specialties, including orthopedic surgery, general surgery, gynecology, neurosurgery, thoracic surgery, and gastroenterology. The company was founded by Eugene R. Corasanti in 1970 and is headquartered in Largo, FL.
Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.
